• 上海交通大學(xué)醫(yī)學(xué)院附屬仁濟(jì)醫(yī)院普外科（上海 200127）;

目的  回顧胃癌基因診斷和治療的研究進(jìn)展。方法  復(fù)習(xí)相關(guān)資料，就近年來胃癌基因診斷和治療方面的研究進(jìn)展作一綜述。 結(jié)果  使用基因技術(shù)檢測腫瘤標(biāo)志物對胃癌的早期發(fā)現(xiàn)、預(yù)后監(jiān)測、療效判斷等都具有較大的臨床意義。胃癌的基因治療還有許多問題需進(jìn)一步解決。結(jié)論  基因檢測及治療將成為胃癌診治的重要輔助手段。

引用本文： 沈志勇,劉驊,曹暉. 胃癌基因診斷和治療的研究進(jìn)展. 中國普外基礎(chǔ)與臨床雜志, 2009, 16(6): 500-502. doi: 復(fù)制

1. 楊少輝, 戴冬秋. 腫瘤抑制基因甲基化與胃癌 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2006; 13(5): 614-616.
2. 黃斌, 李昂, 張波, 等. 納米炭吸附5-FU淋巴靶向化療對胃癌組織及轉(zhuǎn)移淋巴結(jié)bcl-2、bax及caspase-3表達(dá)的影響 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2009; 16(1): 18-22.
3. Deng D, El-Rifai W, Ji J, et al. Hypermethylation of metallothionein-3 CpG island in gastric carcinoma [Ｊ]. Carcinogenesis, 2003; 24(1): 25-29.
4. Tanaka H, Yashiro M, Sunami T, et al. ICAM-2 gene therapy for peritoneal dissemination of scirrhous gastric carcinoma [Ｊ]. Clin Cancer Res, 2004; 10(14): 4885-4892.
5. Carneiro F, Oliveira C, Leite M, et al. Molecular targets and biological modifiers in gastric cancer [Ｊ]. Semin Diagn Pathol, 2008; 25(4): 274-287.
6. Ficorella C, Cannita K, Ricevuto E, et al. P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancer [Ｊ]. Oncol Rep, 2003; 10(1): 169-173.
7. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics [Ｊ]. Science, 2001; 293(5532): 1068-1070.
8. Leung WK, Yu J, Ng EK, et al. Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues [Ｊ]. Cancer, 2001; 91(12): 2294-2301.
9. 溫爽, 劉天卿, 李梅, 等. 胃黏膜上皮錯配修復(fù)基因hMLH1表達(dá)在胃癌診斷中的臨床意義 [Ｊ]. 大連醫(yī)科大學(xué)學(xué)報, 2007; 29 (6): 539-541.
10. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice [Ｊ]. Cancer Res, 2004; 64(20): 7183-7190.
11. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy [Ｊ]. Trends Mol Med, 2001; 7(12): 542-547.
12. 何滿西, 李耿, 姚有貴, 等. 胰腺癌細(xì)胞survivin表達(dá)RNAi抑制載體的構(gòu)建及其抑制作用的研究 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2008; 15(11)： 829-834.
13. 張成斌, 燕善軍, 王啟之, 等. survivin基因檢測在胃癌輔助診斷中的應(yīng)用 [Ｊ]. 蚌埠醫(yī)學(xué)院學(xué)報, 2007; 32(6): 649-652.
14. 劉平, 王同杉, 游思洪, 等. livin在人胃癌組織中的表達(dá)及其沉默后對胃癌細(xì)胞凋亡的影響 [Ｊ]. 中華腫瘤雜志, 2007; 29(8): 570-574.
15. 李中福, 王子衛(wèi). 胃癌組織中Livin的表達(dá)及意義 [Ｊ]. 中華消化外科雜志, 2008; 7(3): 177-179.
16. Nishimura T. Total number of genome alterations in sporadic gastrointestinal cancer inferred from pooled analyses in the literature [Ｊ]. Tumour Biol, 2008; 29(6): 343-350.
17. Wen SF, Xie L, McDonald M, et al. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models [Ｊ]. Cancer Gene Ther, 2000; 7(11): 1469-1480.
18. Ohashi M, Kanai F, Ueno H, et al. Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo [Ｊ]. Gut, 1999; 44(3): 366-371.
19. Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer [Ｊ]. World J Gastroenterol, 2006; 12(2): 192-198.
20. Jeong YW, Kim KS, Oh JY, et al. Exogenous wild-type p16INK4A gene induces delayed cell proliferation and promotes chemosensitivity through decreased pRB and increased E2F-1 expressions [Ｊ]. Int J Mol Med, 2003; 12(1): 61-65.
21. Guo C, Ding J, Yao L, et al. Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1 [Ｊ]. Int J Cancer, 2005; 116(1): 155-160.
22. Wels W, Moritz D, Schmidt M, et al. Biotechnological and gene therapeutic strategies in cancer treatment [Ｊ]. Gene, 1995; 159(1): 73-80.
23. Ogiso Y, Sakai N, Watari H, et al. Suppression of various human tumor cell lines by a dominant negative H-ras mutant [Ｊ]. Gene Ther, 1994; 1(6): 403-407.
24. Essner R, Huynh Y, Nguyen T, et al. Functional interleukin-4 receptor and interleukin-2 receptor common gamma chain in human gastric carcinoma: a possible mechanism for cytokine-based therapy [Ｊ]. J Gastrointest Surg, 2001; 5(1): 81-90.
25. Zhao ZG, Shen WL. Heat shock protein 70 antisense oligonucleotide inhibits cell growth and induces apoptosis in human gastric cancer cell line SGC-7901 [Ｊ]. World J Gastroenterol, 2005; 11(1): 73-78.
26. Kosaka K, Yashiro M, Sakate Y, et al. CD80 gene therapy for lymph node involvement by gastric carcinoma [Ｊ]. Int J Oncol, 2004; 25(5): 1319-1325.
27. Yoshida T, Mizuno M, Taniguchi K, et al. Rat glioma cell death induced by cationic liposome-mediated transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment [Ｊ]. J Surg Oncol, 2001; 76(1): 19-25.
28. Matsukura N, Onda M, Shimada T. Possibility and future problems of gene therapy for gastric cancer [Ｊ]. Nippon Geka Gakkai Zasshi, 2001; 102(10): 778-782.
29. Ueda K, Iwahashi M, Nakamori M, et al. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model [Ｊ]. Cancer Res, 2001; 61(16): 6158-6162.
  1. 1. 楊少輝, 戴冬秋. 腫瘤抑制基因甲基化與胃癌 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2006; 13(5): 614-616.
  2. 2. 黃斌, 李昂, 張波, 等. 納米炭吸附5-FU淋巴靶向化療對胃癌組織及轉(zhuǎn)移淋巴結(jié)bcl-2、bax及caspase-3表達(dá)的影響 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2009; 16(1): 18-22.
  3. 3. Deng D, El-Rifai W, Ji J, et al. Hypermethylation of metallothionein-3 CpG island in gastric carcinoma [Ｊ]. Carcinogenesis, 2003; 24(1): 25-29.
  4. 4. Tanaka H, Yashiro M, Sunami T, et al. ICAM-2 gene therapy for peritoneal dissemination of scirrhous gastric carcinoma [Ｊ]. Clin Cancer Res, 2004; 10(14): 4885-4892.
  5. 5. Carneiro F, Oliveira C, Leite M, et al. Molecular targets and biological modifiers in gastric cancer [Ｊ]. Semin Diagn Pathol, 2008; 25(4): 274-287.
  6. 6. Ficorella C, Cannita K, Ricevuto E, et al. P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancer [Ｊ]. Oncol Rep, 2003; 10(1): 169-173.
  7. 7. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics [Ｊ]. Science, 2001; 293(5532): 1068-1070.
  8. 8. Leung WK, Yu J, Ng EK, et al. Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues [Ｊ]. Cancer, 2001; 91(12): 2294-2301.
  9. 9. 溫爽, 劉天卿, 李梅, 等. 胃黏膜上皮錯配修復(fù)基因hMLH1表達(dá)在胃癌診斷中的臨床意義 [Ｊ]. 大連醫(yī)科大學(xué)學(xué)報, 2007; 29 (6): 539-541.
  10. 10. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice [Ｊ]. Cancer Res, 2004; 64(20): 7183-7190.
  11. 11. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy [Ｊ]. Trends Mol Med, 2001; 7(12): 542-547.
  12. 12. 何滿西, 李耿, 姚有貴, 等. 胰腺癌細(xì)胞survivin表達(dá)RNAi抑制載體的構(gòu)建及其抑制作用的研究 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2008; 15(11)： 829-834.
  13. 13. 張成斌, 燕善軍, 王啟之, 等. survivin基因檢測在胃癌輔助診斷中的應(yīng)用 [Ｊ]. 蚌埠醫(yī)學(xué)院學(xué)報, 2007; 32(6): 649-652.
  14. 14. 劉平, 王同杉, 游思洪, 等. livin在人胃癌組織中的表達(dá)及其沉默后對胃癌細(xì)胞凋亡的影響 [Ｊ]. 中華腫瘤雜志, 2007; 29(8): 570-574.
  15. 15. 李中福, 王子衛(wèi). 胃癌組織中Livin的表達(dá)及意義 [Ｊ]. 中華消化外科雜志, 2008; 7(3): 177-179.
  16. 16. Nishimura T. Total number of genome alterations in sporadic gastrointestinal cancer inferred from pooled analyses in the literature [Ｊ]. Tumour Biol, 2008; 29(6): 343-350.
  17. 17. Wen SF, Xie L, McDonald M, et al. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models [Ｊ]. Cancer Gene Ther, 2000; 7(11): 1469-1480.
  18. 18. Ohashi M, Kanai F, Ueno H, et al. Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo [Ｊ]. Gut, 1999; 44(3): 366-371.
  19. 19. Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer [Ｊ]. World J Gastroenterol, 2006; 12(2): 192-198.
  20. 20. Jeong YW, Kim KS, Oh JY, et al. Exogenous wild-type p16INK4A gene induces delayed cell proliferation and promotes chemosensitivity through decreased pRB and increased E2F-1 expressions [Ｊ]. Int J Mol Med, 2003; 12(1): 61-65.
  21. 21. Guo C, Ding J, Yao L, et al. Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1 [Ｊ]. Int J Cancer, 2005; 116(1): 155-160.
  22. 22. Wels W, Moritz D, Schmidt M, et al. Biotechnological and gene therapeutic strategies in cancer treatment [Ｊ]. Gene, 1995; 159(1): 73-80.
  23. 23. Ogiso Y, Sakai N, Watari H, et al. Suppression of various human tumor cell lines by a dominant negative H-ras mutant [Ｊ]. Gene Ther, 1994; 1(6): 403-407.
  24. 24. Essner R, Huynh Y, Nguyen T, et al. Functional interleukin-4 receptor and interleukin-2 receptor common gamma chain in human gastric carcinoma: a possible mechanism for cytokine-based therapy [Ｊ]. J Gastrointest Surg, 2001; 5(1): 81-90.
  25. 25. Zhao ZG, Shen WL. Heat shock protein 70 antisense oligonucleotide inhibits cell growth and induces apoptosis in human gastric cancer cell line SGC-7901 [Ｊ]. World J Gastroenterol, 2005; 11(1): 73-78.
  26. 26. Kosaka K, Yashiro M, Sakate Y, et al. CD80 gene therapy for lymph node involvement by gastric carcinoma [Ｊ]. Int J Oncol, 2004; 25(5): 1319-1325.
  27. 27. Yoshida T, Mizuno M, Taniguchi K, et al. Rat glioma cell death induced by cationic liposome-mediated transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment [Ｊ]. J Surg Oncol, 2001; 76(1): 19-25.
  28. 28. Matsukura N, Onda M, Shimada T. Possibility and future problems of gene therapy for gastric cancer [Ｊ]. Nippon Geka Gakkai Zasshi, 2001; 102(10): 778-782.
  29. 29. Ueda K, Iwahashi M, Nakamori M, et al. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model [Ｊ]. Cancer Res, 2001; 61(16): 6158-6162.